•Professor Syed Haq is a Professor of Medicine. He specialises in treating the ageing brain/skin and immune system. He performs cosmetic procedures such as botulinum toxin, dermal fillers and PDO/PCL threads. He is currently an International KOL for Croma and Hugel.
•Since qualifying in 1993, he has authored over 100 peer-reviewed articles/abstracts (e.g., in Nature Medicine & PNAS), and presented numerous meetigs/webinars globally.
•Prof. Haq studied at Imperial College UK, Harvard Medical School and Massachusetts General Hospital, USA. He has overseen several MHRA registered clinical trials in the UK and has been awarded 2 x US FDA Orphan Drug Designations (Systemic Sclerosis and Secondary Progressive Multiple Sclerosis). He led a major multi-national European study for hand rejuvenation (Haq et al., 2010). He is a multi-award winning clinician/scientist – from the Medical Research Council, Wellcome Trust and American Heart Association and American Heart Failure Society. He was AstraZeneca New England Young Investigator of the Year.
•Prof. Haq is the CEO/CMO/Founder of BioImmunitas Ltd which is focused on developing pharmaceutical therapeutics for targeting systemic inflammatory disorders, COVID-19 and anti-senescent longevity therapeutics by recalibration of the innate immune system. BioImmunitas is focused on an IND and clinical trials in Q2 2023.
•Prof. Haq runs his Medicine and Aesthetics clinics in London, Belfast, Londonderry and Dublin.
•Since 2007 he has advised and acted as an International KOL for Merz, Teoxane, Q-med, Bioform, Ipsen, and Galderma; helping to develop innovative treatment approaches and education. He was part of a visionary group of clinicians who created the first university Master’s Program in Aesthetic Medicine in the UK in 2010.
•He has been featured on several cosmetic surgery related articles in the popular press (Tatler, Daily Mail, Metro, Hello Magazine) and television (ITV, KSA2).
